Pandrive Dsr contains Pantoprazole. Pandrive Dsr uses:
Pandrive Dsr is indicated where suppression of acid secretion is of therapeutic benefit. Pandrive Dsr Is registered in the foltawing indications:
|Brand Name:||Pandrive Dsr|
|Therapeutic Class:||Proton Pump Inhibitor|
|Manufacturer:||BROCHEM HEALTHCARE PVT LTD|
|Last Updated:||2020-11-22 18:15:00|
Pandrive Dsr contains Pantoprazole 40.0 Mg. Pandrive Dsr doses
The usual recommended adult oral dose is 40 mg given once daily, preferably in the morning with or without food. The duration of therapy is ranging from 2-8 weeks.
DIRECTION FOR USE OF IV INJECTION: Pandrive Dsr lyophilized powder and 0.9% Sodium Chloride Injection is for intravenous administration only and must not be given by any other route. Pandrive Dsr IV injection should be given as a slow intravenous injection. The solution for IV injection is obtained by adding 10 ml 0.9% Sodium Chloride Injection to the vial containing powder. After reconstitution the injection should be given slowly over a period of at least 2 to 5 minutes. Use only freshly prepared solution. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours.
DIRECTION FOR USE OF IV INFUSION: Pandrive Dsr IV infusion should be given as an intravenous infusion over a period of approximately 15 minutes. Pandrive Dsr IV infusion should be reconstituted with 10 ml of 0.9% Sodium Chloride Injection and further diluted (admixed) with 0.9% Sodium Chloride Injection or 5% Dextrose or Lactated Ringer's Injection to a final volume of 100 ml. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours prior to further dilution. The admixed solution may be stored at room temperature (up to 30° C) and must be used within 24 hours from the time of initial reconstitution.
No potentially life-threatening effects have been reported with Pandrive Dsr. Symptomatic adverse effects include headache and diarrhoea are two common reported adverse effects. Peripheral edema has been occasionally reported in female patients. Other side effects may include abdominal pain, dizziness, nausea, epigastric discomfort, flatulence, skin rash, pruritus etc.
Pandrive Dsr is chemically a novel substituted benzimidazole derivative, which suppresses the final step in gastric acid production by forming a covalent bond to two sites of H+/K+ATPase enzyme system at the secretory surface of the gastric parietal cell. This leads to inhibition of both basal and stimulated gastric effect that persists longer than 24 hours.
Pandrive Dsr is quantitatively absorbed and its bioavailability does not change upon multiple dosing. Pandrive Dsr is extensively metabolized in the liver. Almost 80% of an oral dose is excreted as metabolites in urine; the remainder is found in feces.
Patients should be cautioned that Pandrive Dsr tablet should not be split, crushed or chewed. The tablet should be swallowed whole, with or without food in the stomach. Concomitant administration of antacid does not affect the absorption of Pandrive Dsr.
There is no interaction with concomitantly administered antacids. No dosage adjustment is needed with combination use of the following drugs: Theophylline, Caffeine, Diazepam, Digoxin, Ethanol, Metoprolol, Nifedipine or Warfarin.
There are no adequate or well-controlled studies in pregnant women. Pandrive Dsr should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether Pandrive Dsr is excreted in human breast milk. Pandrive Dsr should be used during lactation only if the potential benefit justifies the potential risk.
It is contraindicated in patients with known hypersensitivity to Pandrive Dsr.
There are no known symptoms of overdosage in humans. Since Pandrive Dsr is highly protein bound, it is not readily dialyzable. Apart from symptomatic and supportive management, no specific therapy is recommended.
Store in a cool, dry place and away from light. Keep out of the reach of children.
Pandrive Dsr Capsule price in India 80.75